Ventac Partners
Kostas Alevizopoulos is an accomplished leader in the biotech and pharmaceutical sectors, currently serving as the Chief Executive Officer of APIM Therapeutics since January 2020, where the focus is on developing the oncology drug candidate ATX-101. As a Partner at Ventac Partners since August 2007, Kostas has contributed to numerous technology-driven projects in biotech, pharma, and medtech. Additionally, Kostas serves as Chief Scientific Advisor at Gerolymatos International SA and as a Strategic Advisor for Exogenus Therapeutics. Previous roles include Chief Executive Officer at Medexis SA and Chief Scientific Officer at PNG Gerolymatos SA, among others. Kostas possesses a Ph.D. in Molecular Biology from the University of Lausanne and a Diploma in Biochemistry and Biology from Ethnikon kai Kapodistriakon Panepistimion Athinon.
This person is not in the org chart
This person is not in any offices
Ventac Partners
1 followers
With offices across Europe, United States and Asia and with our multi-disciplinary Partner and Advisor teams, Ventac Partners strives to provide its clients superior global services delivered locally. Covering Biotech, Pharma and Medtech, we offer hands-on experience and skills required to drive innovative technology-based projects from the laboratory to the market. Over the last 15 years, we have experienced a steadily growing business with industry and academic institutions, we have founded, incorporated and exited several companies together with our partners and investors and consulted on hundreds of different early stage or advanced projects. Ventac Partners is continuously expanding its international presence and remains committed to generate value to its clients and portfolio company partners and investors.